A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : LA / long-acting

[Related PubMed/MEDLINE]
Total Number of Papers: 110
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   LA  (>> Co-occurring Abbreviation)
Long Form:   long-acting
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 A systematic review evaluating the efficacy and factor consumption of long-acting recombinant factor VIII products for the prophylactic treatment of hemophilia A. ABR, rFVIII
2020 Cabotegravir and rilpivirine for the treatment of HIV. ART, CR, PLWH
2020 Evaluation of a Long-Acting Opioid Restriction Policy: Does Restriction Reduce the Need for Naloxone Reversal? CI, OR
2020 Evaluation of the effect of UGT1A1 polymorphisms on the pharmacokinetics of oral and long-acting injectable cabotegravir. PK, UGT
2020 Examining adherence barriers among women with HIV to tailor outreach for long-acting injectable antiretroviral therapy. ART, WIHS
2020 Exploration into the opinions of patients with HIV, healthcare professionals and the lay public of the use of microneedles in clinical practice: highlighting the translational potential for their role in HIV infection. ART, HCPs, LP, MN
2020 Identifying appropriate candidates for long-acting antiretroviral therapy: findings from a survey of health care providers in the ATLAS-2M trial. ART, CAB, HCPs, RPV
2020 Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults. IM
2020 Predicting Pharmacokinetics of a Tenofovir Alafenamide Subcutaneous Implant Using Physiologically Based Pharmacokinetic Modelling. NRTI, PBMCs, PBPK, PrEP, s.c, TAF, TFV, TFV-DP
10  2020 Rod-shape theranostic nanoparticles facilitate antiretroviral drug biodistribution and activity in human immunodeficiency virus susceptible cells and tissues. ARVs, LA-ICP-MS, PK, RPV
11  2020 Synthesis and Characterization of Long-Acting Darunavir Prodrugs. ART, DRV
12  2020 Trans-urocanic acid enhances tenofovir alafenamide stability for long-acting HIV applications. PrEP, TAF, TAFfb, UA
13  2020 Viral load Reduction in SHIV-Positive Nonhuman Primates via Long-Acting Subcutaneous Tenofovir Alafenamide Fumarate Release from a Nanofluidic Implant. ART, NHP, PBMC, SHIV, TAF, TFV-DP
14  2019 2-Hydroxypropyl-beta-cyclodextrin-enhanced pharmacokinetics of cabotegravir from a nanofluidic implant for HIV pre-exposure prophylaxis. ARV, CAB, HIV, INSTI, PK, PrEP
15  2019 A long acting nanoformulated lamivudine ProTide. MDM, NM23TC, PK
16  2019 A Multiple Dose Phase 1 Assessment of Rilpivirine Long Acting in a Model of Preexposure Prophylaxis Against HIV. AEs, PD, PK, PrEP, RPV
17  2019 A Prospective Observational Study to Evaluate the Effects of Long-Acting Somatostatin Analogs on 68Ga-DOTATATE Uptake in Patients with Neuroendocrine Tumors. NETs, SSAs
18  2019 Assessment of the long-acting ivermectin formulation in sheep: Further insight into potential pharmacokinetic interactions. ABM, IVM
19  2019 Characteristics and contraceptive outcomes of women seeking medical or surgical abortion in reproductive health clinics in Cambodia. MOTIF
20  2019 Characterization of a Reservoir-Style Implant for Sustained Release of Tenofovir Alafenamide (TAF) for HIV Pre-Exposure Prophylaxis (PrEP). ARV, PCL, PrEP, TAF
21  2019 Creation of a long-acting rilpivirine prodrug nanoformulation. ---
22  2019 Design, Formulation, and Evaluation of Novel Dissolving Microarray Patches Containing Rilpivirine for Intravaginal Delivery. ARV, HIV, IM, MAPs
23  2019 Healthcare provider perspectives on diagnosing and treating adults with attention-deficit/hyperactivity disorder. ADHD, HCP, NPs, PCPs, SA
24  2019 Mitigation of IV Abuse Through the Use of Abuse-Deterrent Opioid Formulations: An Overview of Current Technologies. ADFs, ER
25  2019 Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination: A comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission. ARV, Hu, NPs, PrEP, PT, T/F, TAF
26  2019 Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study. ART, HIVMQ
27  2019 Predicting Drug-Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modeling. DDIs, PBPK
28  2019 Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies. ARV, HIV, IVIVE, NRTI, SSPNs
29  2019 Synthesis of a long acting nanoformulated emtricitabine ProTide. ART
30  2019 The Patient Perspective: Unmet Treatment Needs in Adults With Attention-Deficit/Hyperactivity Disorder. ADHD, AU, SA
31  2019 Two years in growth hormone 2017-18. rhGH
32  2018 Design, formulation and evaluation of novel dissolving microarray patches containing a long-acting rilpivirine nanosuspension. ARV, HIV, IM, MAPs, RPV
33  2018 Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain. ART, PLHIV
34  2018 Impact of opioid dose reduction on individuals with chronic pain: results of an online survey. CDC, ER, IR
35  2018 Medication use in adults with attention deficit/hyperactivity disorder in a commercially-insured population in the United States. ADHD, DACON, SA
36  2018 Optimizing the preparation and stability of decorated antiretroviral drug nanocrystals. ART, FA
37  2018 Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial. PrEP
38  2018 Treatment patterns among adults with ADHD receiving long-acting therapy. ADHD, CT, PDC, TTD
39  2018 Ultra-long-acting removable drug delivery system for HIV treatment and prevention. ARVs, NHP
40  2017 A mature macrophage is a principal HIV-1 cellular reservoir in humanized mice after treatment with long acting antiretroviral therapy. ART, BM, CAB, RVP
41  2017 Changes in misuse and abuse of prescription opioids following implementation of Extended-Release and Long-Acting Opioid Analgesic Risk Evaluation and Mitigation Strategy. ER, IR
42  2017 Higher bioavailability of doxycycline in broiler chickens with a novel in-feed pharmaceutical formulation. HPLC, MRT, PK/PD
43  2017 Investigational HIV integrase inhibitors in phase I and phase II clinical trials. BIC, CAB, INSTIs, NCINI
44  2017 Long acting systemic HIV pre-exposure prophylaxis: an examination of the field. ---
45  2017 Pharmacokinetics of Conventional and Long-Acting Oxytetracycline Preparations in Kilis Goat. BW, Group I, IM, OTC
46  2017 Relationship between ivermectin concentrations at the injection site, muscle and fat of steers treated with traditional and long-acting preparations. IVM
47  2017 Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant. IGF-I, PEGV, SSAs, SSTRs
48  2017 The effectiveness and safety of same-day versus next-day administration of long-acting granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced neutropenia: a systematic review. FN, G-CSF
49  2016 Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans. UGT
50  2016 Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy. ---
51  2016 Time-to-Cessation of Postoperative Opioids: A Population-Level Analysis of the Veterans Affairs Health Care System. SA, VHA
52  2015 Controlled Substance Prescribing Patterns--Prescription Behavior Surveillance System, Eight States, 2013. ER, MMEs, PBSS, PDMPs
53  2015 Effectiveness and safety of a long-acting, once-daily, two-phase release formulation of methylphenidate (Ritalin LA) in school children under daily practice conditions. CGI, Ritalin LA
54  2015 Health-care costs and utilization related to long- or short-acting antiepileptic monotherapy use. AED, MPRs, SA
55  2015 Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV. PBPK
56  2015 Safety, tolerability and pharmacokinetics of rilpivirine following administration of a long-acting formulation in healthy volunteers. IM, RPV
57  2014 GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting injectable administration in healthy subjects. IM
58  2014 Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus. GSK744, PrEP
59  2014 Pharmacokinetics, safety, and tolerability with repeat doses of GSK1265744 and rilpivirine (TMC278) long-acting nanosuspensions in healthy adults. IM, RPV
60  2014 Use of prescription opioids with abuse-deterrent technology to address opioid abuse. ER, ER oxycodone, ER oxymorphone
61  2013 A pilot study to investigate adherence to long-acting opioids among patients with advanced lung cancer. PHQ-2, SD
62  2013 Class-wide REMS for extended-release and long-acting opioids: potential impact on pharmacies. ER, REMS
63  2013 Design and synthesis of HIV-1 protease inhibitors for a long-acting injectable drug application. PIs
64  2013 Pharmacokinetics of a peroral single dose of two long-acting formulations and an aqueous formulation of doxycycline hyclate in horses. AUC, Dox, Dox-beta, Dox-h, MIC, PK/PD, tmax
65  2012 Evaluation of an experimental urodynamic platform to identify treatment effects: a randomized, placebo-controlled, crossover study in patients with overactive bladder. ITT, MCC, OAB, PD1, PD7, PP, UDS
66  2012 Evolution of opioid risk management and review of the classwide REMS for extended-release/long-acting opioids. ER, FDA, FDAAA, REMS
67  2012 Humanized mice recapitulate key features of HIV-1 infection: a novel concept using long-acting anti-retroviral drugs for treating HIV-1. ART, NOG
68  2012 Natural history of opioid dosage escalation post-injury: a cohort study of injured workers in the State of Louisiana. SA
69  2012 Persistent efficacy of a long acting injectable formulation of moxidectin against natural infestations of the sheep nasal bot (Oestrus ovis) in Spain. ---
70  2012 Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine. ---
71  2012 Risk Evaluation and Mitigation Strategies (REMS) for extended-release and long-acting opioid analgesics: considerations for palliative care practice. ER, FDA, REMS
72  2012 Treatment patterns, adherence, and persistence in ADHD: a Canadian perspective. ADHD, RAMQ, SA
73  2012 Utilization patterns of stimulants in ADHD in the Medicaid population: a retrospective analysis of data from the Texas Medicaid program. ADHD, DPR, SA, SA-A, SA-M
74  2011 Treatment outcomes with methylphenidate formulations among patients with ADHD: retrospective claims analysis of a managed care population. ADHD, CI, HR, MPH
75  2010 Evaluation of the persistent activity of moxidectin (10%) long-acting (LA) injectable formulation against Dictyocaulus viviparus, Haemonchus placei, Trichostrongylus axei and Oesophagostomum radiatum infections in cattle. ---
76  2010 Octreotide long-acting release (LAR): a review of its use in the management of acromegaly. ATG, GH, IGF, LAR
77  2010 Therapeutic and persistent efficacy of a long-acting (LA) formulation of ivermectin against Rhipicephalus (Boophilus) microplus (Acari: Ixodidae) and sera concentration through time in treated cattle. ---
78  2010 Treatment stabilization in children and adolescents with attention-deficit/hyperactivity disorder: data from the Netherlands. ADHD, IR
79  2009 Changes in the use of analogue insulins in 37 206 children and adolescents with type 1 diabetes in 275 German and Austrian centers during the last twelve years. SA
80  2008 Lanreotide Autogel: a review of its use in the management of acromegaly. ATG, GH, IGF-I
81  2008 Spotlight on lanreotide Autogel in acromegaly. ATG, GH, IGF-I
82  2007 Changes and challenges: managing ADHD in a fast-paced world. ADHD, CMAP
83  2007 Predictors of long-acting opioid use and oral versus transdermal route among older Medicaid beneficiaries. aOR, SA, TDF
84  2006 A comparative efficacy of oral prednisone with intramuscular triamcinolone in acute exacerbation of asthma. FEV1, FVC
85  2005 Comparison of carteolol plasmatic levels after repeated instillations of long-acting and regular formulations of carteolol 2% in glaucoma patients. ---
86  2005 Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder. CD, CI, ER, IR, MPH
87  2004 Anti-nociceptive and sedative effects of sufentanil long acting during and after sevoflurane anaesthesia in dogs. ---
88  2004 Effects of subcutaneous injections of a long acting moxidectin formulation in grazing beef cattle on parasite fecal egg reduction and animal weight gain. ADG
89  2004 Evaluation of the chemoprophylactic efficacy of 10% long acting injectable moxidectin against gastrointestinal nematode infections in calves in Belgium. PT, U tyr
90  2004 Long-acting injectable risperidone. ---
91  2004 Prophylaxis of postoperative nausea and vomiting with oral, long-acting dimenhydrinate in gynecologic outpatient laparoscopy. PACU
92  2002 Efficacy of a new long-acting formulation of ivermectin and other injectable avermectins against induced Psoroptes ovis infestations in cattle. LAI
93  2001 Pharmacokinetics and residues in milk of oxytetracyclines administered parenterally to dairy goats. CF, CK, IM, LDH, OTC
94  1998 Effect of calcium antagonists on sympathetic activity. NE, SA
95  1997 Effect of calcium antagonists on plasma norepinephrine levels, heart rate, and blood pressure. NE, SA
96  1995 Pharmacoclinical correlations in schizophrenic patients treated with haloperidol decanoate: clinical evaluations, concentrations of plasma and red blood cell haloperidol and its reduced metabolite, and plasma homovanillic acid. HAL, HVA, RBC, RHAL
97  1994 Effect of propranolol on prevention of first variceal bleed and survival in patients with chronic liver disease. ---
98  1993 Comparison of propranolol LA 80 mg and propranolol LA 160 mg in migraine prophylaxis: a placebo controlled study. ---
99  1992 Treatment of Brucella melitensis infection in sheep and goats with oxytetracycline combined with streptomycin. IM, OTC, ST
100  1991 [Slow-release salbutamol in the treatment of nocturnal asthma. Result of a comparative study vs. long-acting theophylline]. SRS